PACCARB Public Meeting | May 21, 2024 | Day 1, Part 4 of 4

USDOHAHS
156 followers
Jun 4, 2024
U.S. Department of Health and Human Services (HHS) | http://www.hhs.gov | HHS Privacy Policy | http://www.hhs.gov/Privacy.html
>> Jomana Musmar: All right. Well, welcome back everyone. We are now going into the
public comment portion of our day. We are delighted to have some associations and
organizations with us. Commenters have had the option to send in their written
comments to PACCARB at HHS. gov. We have our live commenters here today that have pre-registered,
and I am delighted to welcome, John Alter from the AMR Action Fund. You have the floor.
>> John Alter: Thank you, Jomana. PACCARB members. My name is John Alter and I lead
the external affairs team for the AMR Action Fund. Thank you for the opportunity to provide
recommendations on the U.S. government's role in addressing AMR in conflict zones,
which will be the subject of panel three tomorrow. While conflicts in Ukraine and
Gaza dominate the news, worldwide at least 110 armed conflicts are ongoing. As the fund's CEO,
Henry Skinner, wrote in this winter's Harvard Public Health, the causes of AMR in conflict
settings are multifactorial. Soldiers sustain catastrophic injuries and can
require international transport. Hospitals, care centers and ad hoc clinics become overburdened
and lack basic supplies and infection control capacity. As noted by the patient advocate
from Ghana we heard from previously. Civilians are displaced and may be relocated to refugee
camps. And damaged infrastructure leads to poor sanitary conditions. The danger of the conflict
itself is paramount, but the impact of uncontrollable infections is deadly too.
As the world's largest investor in the development of antimicrobial treatments, the AMR Action Fund
is committed to enabling the launch of up to four new antimicrobials by 2030. However,
longer term policy changes are necessary to make the innovation ecosystem sustainable,
to reinvigorate the antibiotic and antifungal pipelines, and support enhanced defense
and surveillance measures. We recognize the need strengthen U.S. leadership globally to meet this
critical moment in the fight against AMR and offer the following policy recommendations.
First, invest in targeted antimicrobials to overcome rising biosecurity threats identified
in the recently updated U.S. government policy for oversight of dual use research of concern and
pathogens with enhanced pandemic potential. The select agents and toxins subject to the
policy include several bacterial pathogens that pose a significant threat to biosecurity. While
the National Stockpile -- Strategic National Stockpile serves as a repository for antibiotics
and medical material that can be used in the event of the outbreak, they are often broad spectrum,
and the market for R&D continues to decline as these pathogens evolve. We recommend that the
U.S. replace volume based procurement with a subscription model framework for critical need
antibiotics via multi-year contracts to ensure adequate solution for rising biosecurity threats.
Second, we urge sustained CDC funding for detection and surveillance to better
monitor and track priority bacterial and fungal pathogens in accordance
with the 2024 National Blueprint for biodefense recommendations.
Third, increase collaborations among federal agency, university and professional site
society partners to incentivize research and training programs in areas that intersect with
AMR similar to the comments made this morning by IDSA as Amanda Jezek. Next,
develop institutional federal research mechanisms that allow infectious disease
trainees to easily identify and meaningfully interact with qualified potential mentors at
the federal and institutional levels, and finally appoint a federal champion
for AMR to represent U.S. policy positions on the global stage. Thank you for your leadership,
and please contact us if we can assist in advancing the solutions in combating AMR.
>> Jomana Musmar: Thank you, Mr. Alter. On behalf of the AMR Action Fund,
I'd like to call on Jim Boyce from NIAID next to me. Mr. Boyce,
are you with us? Okay. Next we'll go to Doctor Sameer Kadri, NIH Clinical Center.
>> Sameer Kadri: Thank you Jumana. I'd like to start by saying that
this has been a wonderful meeting and I applaud everybody's efforts. I am an ICU
clinician and AMR epidemiologist at the NIH Clinical Center in Bethesda, and I'm here to,
provide some suggestions to you guys about AMR data and metrics and how we can do better.
The Covid 19 pandemic showed us that critical and timely data are really essential and the
dissemination of that is essential to move the dial for action. Why can't we do the same for
AMR? The U.S. is a developed nation. We have -- we are sitting on a lot of data. Unfortunately,
the data is siloed, and I believe that the PACCARB has the power to make recommendations such that
the wand is moved up at a very high level that may result in dissolution of these firewalls
so that de-identified data could be accumulated around AMR. And we could use those data to apply
more sensitive metrics, not only mortality but other non-mortality outcomes as well disability,
morbidity, readmission, nursing home status. These are all important to clinicians and to patients
who have AMR infections. And while it's difficult to attribute the impact of the interventions to
the outcomes that we see, I think if we see improved mortality and non-mortality outcomes
for patients with resistance, I think most people will agree that PACCARB has done its job.
>> Jomana Musmar: Thank you, Doctor Kadri. Thank you for joining us. Next,
virtually, I would like to call on Tara Burke from Advamed. Are you with us?
>> Tara Burke: Yes. I'm here. Can you hear me?
>> Jomana Musmar: Yes, we can hear you. The floor is yours.
>> Tara Burke: Okay, great. Thank you. Good afternoon. My name is Tara Burke, vice president
of Payment and Healthcare Delivery Policy at the Advanced Medical Technology Association,
or Advamed. Advamed is the world's largest medtech association and its Advamed DX division represents
over 70 of the world's leading manufacturers of in vitro diagnostics, including large,
small and startup companies. Thank you for this opportunity to share our perspectives today.
In vitro diagnostic tests serve as a cornerstone in combating AMR. Diagnostic tests are pivotal for
accurate identification and differentiation of bacterial from viral infections,
which significantly aids and the judicious use of antimicrobials. By assisting health
care professionals in determining the most effective treatment strategies,
diagnostic tests significantly reduce unnecessary
antibiotic prescriptions and help stem the tide of rising resistance.
Our industry continues to innovate, developing advanced diagnostic tools that not only provide
faster and more accurate results, but also ensure appropriate antibiotic stewardship.
These technologies allow for the rapid detection of pathogens and their resistance patterns,
enabling targeted treatment that is both effective and economical. The
role of diagnostics and managing sepsis, tuberculosis and other critical conditions
has proven to reduce hospital stays and health care costs significantly.
The diagnostics industry is committed to ensuring timely access to these innovative
technologies needed to mitigate the impact of AMR and support efficiencies in health systems.
We believe AMR policy should strengthen access and utilization of diagnostics,
including recognition of the critical role they play in AMR stewardship programs,
as well as the role they play in supporting evidence generation through surveillance.
A key driver of adoption of in vitro diagnostic tests to further AMR is appropriate reimbursement
pathways. Implementing reimbursement policies, including those for Medicare beneficiaries that
support the uptake and implementation of such technologies will help reduce inappropriate
prescribing practices and lead to improvements in patient outcomes. We appreciate that the current
National Action Plan on Combating Antibiotic Resistant Bacteria includes within it a priority
to develop incentives and reimbursement strategies support uptake of diagnostics.
We believe this is a step in the right direction, but believe more can be done, particularly through
expansion of existing programs within the centers for Medicare and Medicaid
Services. Thank you again for this opportunity. We look forward to continuing our collaborative
efforts with all state [unintelligible] to overcome the challenges of AMR. Thank you.
>> Jomana Musmar: Joining us, Tara on behalf of the Advamed DX. Next we
have Megan Coffee with the International Rescue Committee. Megan, are you with us?
>> Megan Coffee: Yes.
>> Jomana Musmar: All right. Floor is yours.
>> Megan Coffee: Great. My name is making coffee, and I'm an infectious disease doctor here in New
York City. I'm at NYU here in New York, but I'm here as the communicable disease advisor
for the International Rescue Committee. We're an organization based in New York City that works
in 35 countries, up to 50 at a time, working on helping people respond to conflict and disaster.
And so we're working with the most vulnerable people. And I think for too long and I think this
group I'm preaching to the choir here, we've often seen AMR is not a primary issue and
not as a population that was affected, whereas we're finding incredible levels of resistance,
of course, in the populations where we work. And we're working particularly in three countries.
Nigeria, in areas affected by Boko Haram in the northeast, in South Sudan and in Yemen. All
countries that have been affected by conflict and where we've been seeing incredible levels of AMR.
We're working with USAID, BHA, to form a technical advisory group, because I think it's incredibly
important for a number of these -- the different actors, we often talk amongst ourselves and MSF,
Africa, CDC, IMC, U.S., CDC, all part of this to try to really advise on how we can
think more about humanitarian conflicts and these vulnerable populations. And
it's AMR in these crises where increasingly climate change is hitting against violence,
is hitting against mobility that we are seeing real perfect storms for creating AMR.
So malnutrition, if you've never gotten to see a malnutrition ward, that's great. It tends to
be a place where you have the most vulnerable children together, all sick, all having diarrhea,
needing antibiotics, having measles, having malaria, having cholera, and all of these
overlapping levels of antibiotics. We end up with incredible resistance. We have outbreaks.
We have empiric use of antibiotics. Most people in humanitarian conflicts
are children. The pediatric infections and of course IPC, no running water and facilities,
no gloves and of supplies for PPE and needing to really change the culture in order to have care
really center on making sure we're doing no harm, having no IPC concerns. And then
recognizing that communities themselves, how they understand their health problems.
If you've come out of a conflict, you're relying on yourself. You're relying on your family,
relying on your community. And we found that in these areas that we've been studying, particularly
that four out of five people reported that they had taken antibiotics before they came to the
clinic. And also that four out of five of their youngest children had had an antibiotic before
coming to the clinic. And that almost everyone had an antibiotic in the last year. And that 5%,
only of children had not had an antibiotic. So just recognizing the really high level of
antibiotic use and the need to understand is more than just microbiology. Understanding
really how communities are using antibiotics, how they understand the infections. Whether
they think they need to take an antibiotic to prevent a cold, to prevent diarrhea. And then
also understanding vaccine hesitancy has really changed in the wake of Covid and understanding
how we're really meeting these needs. And that's it. Thank you for having me. Over.
>> Jomana Musmar: Megan, thank you so much for joining us on behalf of the International
Rescue Committee. Next, we have David Gross from Arch Stone medical. David, are you with
us? David Gross, Arch Stone medical. Oh, there you go. Hi. Can you hear us? We can't hear you.
>> David Gross: You hear me now?
>> Jomana Musmar: Yes. Ok. Sorry about that.
>> David Gross: Thank you. So I would like to thank you for giving me the opportunity
to speak today. My name is David Gross. I am the co-founder of Arch Stone. At Arch Stone,
we are pioneers in the field of antimicrobial stewardship, leveraging cutting edge technology
to combat the growing threat of AMR. And we offer precise infectious disease treatment guidance,
ensuring that physicians are empowered with the knowledge they need to make informed
prescription decisions. So I commend the work being done by the committee
and my fellow colleagues in the global fight against an equitable stewardship.
But resistance. But I would like to make a strong call to action. Often we get distracted
by defining, discussing, and analyzing the issue. But this stop short of actually trying
to solve it. So before breaking for lunch earlier today, there was a great discussion among the
panel about the need for diagnostics coupled with prescription guidance. And just earlier there was
talk about labs needing more infectious disease expertise. So I've been sitting here watching
this all day and we tell you this is not a future aspiration. It's here now and we have it today.
Companies like Arch Stone are at the forefront of addressing this issue. We're in the midst of
an AI revolution right now and in Arch we'd like to define AI as anti-microbial intelligence. We
integrate directly with diagnostic laboratories to provide precision guided infectious disease
treatment guidance to physicians. At the moment they receive their lab results. So this helps
them make informed decisions, ensuring that the right antibiotic is chosen for the right infection
at the right time. And in many situations, we actually recommend the use of no antibiotics at
all. By integrating with Arch Stone, physicians have instant access to infectious disease
expertise, regardless of the size or staff of the lab. So this allows any lab anywhere in the world
to bring actual infectious disease knowledge to their users through our global guidance feature,
which are bringing infectious disease guidance everywhere, in any language, while also taking
into consideration the specific needs of that region or the developing or resource limited.
So the [unintelligible] knowledge when it comes to proper antimicrobial use can't
be overstated. Despite the critical advances we've made, antimicrobial stewardship remains
relatively obscure. Laboratories routinely test sensitivities for dozens of drugs,
many of which are not relevant to the specific infection being treated. And this often leads to
misguided prescription practices contributing to the rise of antibiotic resistance. And molecular
testing was an exciting development since it unlocked the potential of identifying resistance
genes. But many doctors did not understand the results and actually overprescribed antibiotics
to cover them. Unfortunately, the reaction from CMS and some private insurance companies was
actually to cut reimbursement for some types of testing and discourage active. And this is
not the correct response. We should not avoid new technology due to a lack of understanding,
but rather embrace it and educate ourselves on how to apply it, and it can be part of solution.
Solutions like Arch Stone can make the data valuable and usable, helping doctors prescribe
responsibly, leading to proactive antimicrobial stewardship and improving patient outcomes. So,
insurance companies and government agencies hold significant power to mandate, reimburse, and push
for the adoption of technologies that facilitate real antimicrobial stewardship. Incentives drive
innovation, and by incentivizing clinicians and health care institutions to participate
in stewardship, we can drastically reduce the number of prescriptions written empirically
where antibiotics are prescribed based on guesswork rather than specific, actionable
data. I implore those of you on this committee listening in today in positions of influence to
embrace new technologies and incentivize the use of services like Arch Stone to provide
antimicrobial stewardship with every infectious disease result. By doing so, we can ensure that
doctors are writing prescriptions correctly, actively reducing the misuse of antibiotics,
shortening the duration, and in some cases, awarding the use of antibiotics altogether.
Last year, one of my fellow co-founders actually addressed this committee,
and while there were some nods of recommendation from the assembled group, nothing more came of
it. But in the year since, Arch Stone alone generated a quarter of a million treatment
recommendations for physicians based on lab result data from labs across the U.S. and parts
of South America. So let's work together. It's not let yet another year go by without taking
the action we can say that saves billions of lives. Thank you very much for your time.
>> Jomana Musmar: Thank you David. On behalf of Arch Stone Medical, I appreciate you joining us.
And that wraps up our public comment section. Next, we'll transition to the innovation
spotlight. As you all know, to highlight new and emerging technologies in the fight against AMR,
we're excited to announce to continue this public comment portion to our meetings that
are dedicated more to startup companies and innovations to showcase their work in the
battle against AMR. Like our traditional public comments section of the day,
pre-registered companies have an opportunity to share their work with all of us. The spotlight
was open to all interested companies with a technology directly related to combating AMR, and
each presenter will have five minutes and there will be no Q&A portion following each speaker.
Next we have -- oh, I believe we have a public commenter that just came in. Jim Boyce, NIAID. Are
you with us? Sorry. We're gonna go backwards. Jim, did you join? Jim Boyce. Last call.
Okay. We're going to keep going with the innovation spotlight then. Everything I said
ditto. [Laughs] We're just going to keep going. All right. So we are going to start with Lumos.
>> Annie Bell: Hi there.
>> Jomana Musmar: Hi. Thank you for joining us. Miss Bell. The floor is yours.
>> Annie Bell: Thank you. Thank you for the opportunity to discuss, FebriDx today. My
name is Annie Bell. I'm the head of medical affairs for Lumos Diagnostics and conducting
other clinical research for our products there, including FebriDx. Next slide, please.
So FebriDx is a simple, all in one point of care assay that can be used at the bedside
for clinicians who are making decisions. And the results can be used in the moment to determine
whether or not a patient has a bacterial infection or non-bacterial infection when
they present with acute -- signs and symptoms of acute respiratory infection. So very common
reason for prescribing antibiotics in the U.S. So FebriDx has FDA clearance in the U.S. for
use in urgent care in emergency departments. And it can reliably differentiate between a
bacterial and non-bacterial infection in patients who present with that acute respiratory syndrome.
It can ensure that bacterial infections are not missed. So in patients who do have them
and could benefit from antimicrobials and also ensures that with a high negative predictive
value that for bacterial infection, that antibiotics are not needed. And identifies those
patients who may not benefit from antibiotics and helps protect them from the negative sequela
associated with giving them antibiotics when they're not needed. Next slide please.
So the test works by using two host response biomarkers. The first one may be familiar to
some of you, which is referred to as C-reactive protein. So C reactive protein is of acute phase
reactant, that's produced in response to inflammation including infection. It can
be elevated as a potent stimulus for bacterial infection. The other host response biomarker
that's used on this, on our test is, a mix of virus resistance protein A or MXA. And it's
produced in response to viral infection. The innate immune response releases interferon. And
that up regulates the production of MXA. MXA has low base levels. And therefore, it's more specific
to viral infections where CRP can be elevated at certain levels are more sensitive to bacterial
infections. So independent the two biomarkers are not sensitive nor specific enough to detect
or rule out bacterial infection. But when paired together, they have a high sensitivity,
specificity, and negative predictive value for detecting and ruling out bacterial infection,
therefore, determining when patients may or may not benefit from antibiotics. Next slide please.
So it's a very simple to use test. Like I mentioned before, it can be used right in the
patient visit, by clinicians to make decisions about whether or not a patient has a bacterial
infection and would benefit for an antibiotic, or more likely, does not have a bacterial infection
and may not benefit. So the Landsat is built in its, retractable land set. So there's just,
removal of a safety protective tab. And then the finger is clean, punctured with the test and
just a small drop. Five microliters of blood is obtained, placed directly in the blood collection
tube that works with capillary action. The arm is rotated, it's applied to the test, and then the
buffers release is also incorporated into the test. And it works, via lateral flow. And then
there's built-in controls and quality assurance to ensure that the blood has transferred. And once
the blood is transferred and about ten minutes has passed, the clinician can interpret the test
results to determine if a bacterial infection is or is not present. Next slide please.
So, like I said, FebriDx is a simple point of care assay that's available in the U.S.
currently. And it has been validated, in a multicenter prospective U.S trial, under – with
20 point care sites that were physician offices, urgent care centers and emergency departments.
FebriDx was compared to a clinical reference algorithm that incorporated bacterial culture,
multiplex PCR and measures of host immune response and then had expert adjudication. So was compared
very rigorously basically and was determined to be very sensitive and specific for detecting and
rolling out bacterial infection. So 93% positive predictive agreement, a negative predictive
agreement of 80% and, ruled out bacterial infection with almost a 99% negative predictive
value. So really gives clinicians the confidence when a bacterial infection is there, a patient
really needs an antibiotic, and then supports the antimicrobial stewardship by identifying
patients with a high degree of reliability do not have bacterial infection and may not benefit from
the antibiotic. So it empowers clinicians in the moment, with something tangible to
discuss with their patients when they don't need antibiotics. And it's also very affordable tests.
Like I said, it's a simple lateral flow assay. And that's all I have for today. So thanks very
much for the opportunity and for your efforts, as it relates to antimicrobial resistance.
>> Jomana Musmar: Thank you so much for joining us on behalf of
Lumos Diagnostics. Next, we have Elemeno Health. Are you with us?
>> Arup Roy-Burman: Yep. I'm here. Doctor Arup Roy-Burman. I am, founder and chief
medical officer at Elemeno. So, I'm former medical director of the ICU at UCSF children's, and there
we struggled with how do we keep our staff on the same page with constantly changing information,
complicated by constantly changing staff? And when we look at trying to get information to our
people, it's really about getting them to learn. You're trying to change behaviors. And when you
think about it, even for yourself and how we learn today, when we get information in large chunks,
it goes in one ear and it goes out the other. How could we take critical information,
of which antimicrobial stewardship was just one part of it? How could we get it
in a way that it would stick? So what we realized was the best type of information
is the information you get in context when you're dealing with that septic patient.
That's when I want that information. Just in time. And for the information,
we want it in small chunks. We see today with our staff and our team members, attention spans are
getting shorter and shorter and shorter. You have a brief moment and you've got to hit it hard. And
you do it in a multimedia format that people can understand, get in and get out. So what
we created was a just-in-time microlearning application customized for frontline teams.
Our big picture goals was how could we streamline how we would train and orient
our staff on any myriad of different topics, including of which is antibiotic stewardship?
And then how can we use this just-in-time context to be able to decrease variation,
to be able to improve standardization, improve predictability, and thereby improve safety?
And finally, how could we do it in a way that was local? Because the reality is, frontline
staff don't care much about national guidelines. They want to know about how does that guideline
apply in my house, with my resources, with my formulary, with my patients? We need to give
that customized experience that helps the staff in their house in the moment. Next slide please.
So, this is, you know, our existing world and hopefully it all resonates with you all. You know,
the frontline experience is chaos. We've got operational information from management. We've
got training coming from all of our different specialists and our educators. We're hearing
system wide standards as well as my unit specific information. And it is sitting in binders and
fliers and dumped in SharePoint. It's thrown above the toilet in the bathroom, God knows what version
that is. And in desperation, if I can't find it, I'll go to Google and who knows what I'll
find there. We take all of that and we simplify it into a one stop shop, gave it to the organization,
customized to that individual unit in a multimedia format. Next slide.
I'm sure all of you are familiar with the types of things on the left panel. We see
this for antibiotics all the time. All types of decision guidelines. Lots of efforts gone
into it. The reality is it sits in a drawer somewhere or in a binder or shoved up in
somebody's pocket or briefcase at the moment that it's needed. Few people pull it out,
find it, and are able to use it. The key is we need to make that information one,
accessible in the moment so you can just punch it in, boom! It comes up to you and it needs
to be digestible. Take away that cognitive overload so I can just quickly answer some
questions and see what I need to do. That's what we do. We transform your knowledge and we make it
accessible and digestible in just-in-time multimedia, microlearning. Next slide.
The end result is that it works as seen there at UCSF, one of the top ranked, you know,
hospital systems in the country. We were able to cut [unintelligible] 50% getting everybody
on the same page. Children's New Orleans published 75% decrease in serious patient
harm and looking also in the UCSF ecosystem and the children's hospital, 85% reduction
in C diff infections. We're doing this with hospitals around the country. And the beauty is,
is that everybody is taking national guidelines or guidelines that each one is developed that is
going well, sharing it with others and adapting it to the needs of their house to give their
team a very personal and relevant experience and in this way, getting everybody engaged,
whether it is antibiotic stewardship. It's about just orienting as a new nurse to various
products. All of those things coming into a simple one stop shop. Because the reality is,
is people don't want a myriad of point solutions. They can't remember where it is. We are living in
a world of connectivity. We need to bring it all together in one place and keep it personal. Keep
it, you know, specific to your needs, and do it in a way that management gets feedback on
what works and what doesn't, and they can iterate from there. Thank you very much.
>> Jomana Musmar: Thank you for joining us. Doctor Burnham from Elemeno Health. All right.
Well that concludes the innovation spotlight portion of our day. I'd like to thank all of
our panelists for being with us, both in person and virtually. I'd like to thank
our council members for all of your feedback and comments, and especially our moderators
for today for navigating the two panels that we have. I'm going to open it up for
Doctor Plummer and Doctor Jason Newland to close us out until we prepare for tomorrow.
>> Jason Newland: Thanks, everybody. Thanks to the public commenters and the innovative
spotlight. It's a great day. Thanks to the council again for all the hard work done on the global
AMR report. Super proud of all of us and, getting that done. And, yeah big shout out to our PACCARB
staff. All of you rocked it. And appreciate all that you did to make sure that happened.
Look, I think it was amazing, as usual. I think we're all. I'm still thinking about my two pets
at home. Frankie and Chicken. And whether this can allow me to get rid of them. I'm
just kidding. I'm kidding Doctor. But no, I think what we love about these sessions is we learn,
right? And we get to learn new things and talk about issues that are germane to what our charge
has been from the beginning of PACCARB ten years ago. And so I, again, I appreciate
the discussions and everyone's inputs and I look forward to more of that tomorrow.
>> Paul Plummer: All right. Thank you, Doctor Nuland. I echo Jason's comments. I want to express
my appreciation to all of our PACCARB Council members. RGS, SGS, affiliates. Certainly want to
thank our speakers for taking your time to share your expertise and knowledge with us. It's been a
full day. We started the morning with finalizing our report on collaborative global leadership in
combating AMR. And that's been a lot of work. I want to thank, as Jason did, the working group,
the entire council, and particularly our staff who has worked tirelessly to make edits to get
these out for working group feedback, to line up speakers to address topics. And we do truly
have one of the best staffs that you can imagine. And so, Jumana smiling because
she knows it's true. We do. And so what we do is largely because of the support they provide us.
And then we continue today with several, just, profoundly interesting panels. You know,
we saw a number of narratives and stories about the impacts of AMR on
patients lives and how important that is. And that's important to remind us of why we are
doing what we're doing here today and tomorrow. And then we saw, you know, an outstanding panel
here on the companion animals and that one health interface and just how important
that is. And often how, you know, I think as Doctor Wiess [spelled phonetically] started
that conversation when we talk about animals in antimicrobial resistance and one health,
many people's minds jumped to livestock and livestock production, which certainly is hugely
important in that space. But the interaction that many of us have with our companion animals,
that live in our houses and sleep in our beds and interact with our kids and do all
of the different activities. For most of us, that's a lot more interaction,
as was pointed out by several speakers then we have with livestock, for instance.
So, and then finished out with some very helpful comments from public comments and the innovation
spotlight. So as we prepare to break for today, I would encourage all the council
members and staff to enjoy our evening, be proud of what we accomplished today,
take the evening off and enjoy our fellowship and conversation. And we will start back at 9
a. m. in the morning. We have two -- several phenomenal panels again tomorrow on conflict
zones and drug resistance. And then also the unequal exposure, unequal risk, environmental
racism and drug resistance. And so [inaudible] just live tomorrow, and so enjoy your evenings.
>> Male Speaker: Produced by the U.S. Department of Health and Human Services.
